What is a treatment goal of montelukast related to asthma?

Montelukast is a leukotriene receptor antagonist primarily used in the management of asthma. Its treatment goal related to asthma is focused on preventing bronchoconstriction, especially during physical exertion, which is known as exercise-induced bronchoconstriction. By blocking the action of leukotrienes—substances in the body that cause inflammation, bronchoconstriction, and mucus production—montelukast helps to improve airflow and reduce the frequency and severity of asthma symptoms. This makes it particularly beneficial for individuals who experience asthma symptoms triggered by exercise.

The other options reflect outcomes that are counterproductive to asthma management. For instance, increasing asthma symptoms, the frequency of asthma attacks, or reducing overall fitness would not align with effective asthma treatment strategies, which aim to minimize symptoms, enhance lung function, and improve the quality of life for individuals with asthma. Thus, the correct focus of montelukast's use is to prevent exercise-induced bronchoconstriction and maintain better control over asthma symptoms.